Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.

摘要: Summary Background Seven-valent pneumococcal conjugate vaccine (PCV7) had profound public-health impacts and is considered cost-effective potentially cost saving. Two new PCVs have been launched, a 10-valent (PCV10) 13-valent (PCV13). We examined economic of PCV pediatric national immunization programs (NIPs) in Germany, Greece, the Netherlands. Methods A decision-analytic model was developed to estimate impact PCV13, PCV7, on invasive disease (IPD), pneumonia (PNE), acute otitis media (AOM). Using epidemiological data, we calculated cases IPD, PNE, AOM, using country-specific incidence, serotype coverage, sequelae, mortality, effectiveness, indirect effects, costs, utilities. Direct effects for PCV13- PCV10-covered serotypes were assumed similar PCV7. PCV13 confer an effect, while PCV10 not. Assumptions tested sensitivity analyses. Results In NIP, estimated eliminate 31.7%, 46.4%, 33.8% IPD Netherlands, respectively. Compared with PCV7 PCV10, found be or saving all when included. Conclusions Pediatric NIPs Europe are expected dramatic